377 related articles for article (PubMed ID: 36802876)
41. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
Connolly SJ; Sharma M; Cohen AT; Demchuk AM; Członkowska A; Lindgren AG; Molina CA; Bereczki D; Toni D; Seiffge DJ; Tanne D; Sandset EC; Tsivgoulis G; Christensen H; Beyer-Westendorf J; Coutinho JM; Crowther M; Verhamme P; Amarenco P; Roine RO; Mikulik R; Lemmens R; Veltkamp R; Middeldorp S; Robinson TG; Milling TJ; Tedim-Cruz V; Lang W; Himmelmann A; Ladenvall P; Knutsson M; Ekholm E; Law A; Taylor A; Karyakina T; Xu L; Tsiplova K; Poli S; Kallmünzer B; Gumbinger C; Shoamanesh A;
N Engl J Med; 2024 May; 390(19):1745-1755. PubMed ID: 38749032
[TBL] [Abstract][Full Text] [Related]
42. Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study.
Singer AJ; Concha M; Williams J; Brown CS; Fernandes R; Thode HC; Kirchman M; Rabinstein AA
West J Emerg Med; 2023 Sep; 24(5):939-949. PubMed ID: 37788035
[No Abstract] [Full Text] [Related]
43. Andexanet alfa for the reversal of factor Xa inhibitors.
Favresse J; Hardy M; van Dievoet MA; Sennesael AL; Douxfils J; Samama CM; Vornicu O; Dincq AS; Lessire S; Mullier F
Expert Opin Biol Ther; 2019 May; 19(5):387-397. PubMed ID: 30974977
[TBL] [Abstract][Full Text] [Related]
44. Modeling the Clinical Implications of Andexanet Alfa in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage.
Chuck CC; Kim D; Kalagara R; Rex N; Madsen TE; Mahmoud L; Thompson BB; Jones RN; Furie KL; Reznik ME
Neurology; 2021 Nov; 97(21):e2054-e2064. PubMed ID: 34556569
[TBL] [Abstract][Full Text] [Related]
45. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation.
Carpenter E; Singh D; Dietrich E; Gums J
Ther Adv Drug Saf; 2019; 10():2042098619888133. PubMed ID: 31807265
[TBL] [Abstract][Full Text] [Related]
46. [Andexanet alfa: the best antidote for factor Xa inhibitors?].
Klok FA; Huisman MV
Ned Tijdschr Geneeskd; 2019 Jun; 163():. PubMed ID: 31283119
[TBL] [Abstract][Full Text] [Related]
47. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
[TBL] [Abstract][Full Text] [Related]
48. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.
Sutton SS; Magagnoli J; Cummings TH; Dettling T; Lovelace B; Christoph MJ; Hardin JW
J Thromb Thrombolysis; 2023 Jul; 56(1):137-146. PubMed ID: 37219827
[TBL] [Abstract][Full Text] [Related]
49. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
[TBL] [Abstract][Full Text] [Related]
50. Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data.
Frol S; Oblak JP; Šabovič M; Kermer P
CNS Drugs; 2024 Mar; 38(3):163-168. PubMed ID: 38396232
[TBL] [Abstract][Full Text] [Related]
51. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
Ghadimi K; Dombrowski KE; Levy JH; Welsby IJ
Expert Rev Hematol; 2016; 9(2):115-22. PubMed ID: 26686866
[TBL] [Abstract][Full Text] [Related]
52. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM
Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008
[TBL] [Abstract][Full Text] [Related]
53. Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.
Lu G; Lin J; Bui K; Curnutte JT; Conley PB
Res Pract Thromb Haemost; 2020 Nov; 4(8):1282-1294. PubMed ID: 33313467
[TBL] [Abstract][Full Text] [Related]
54. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
Kaide CG; Gulseth MP
J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
[TBL] [Abstract][Full Text] [Related]
55. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
Panos NG; Cook AM; John S; Jones GM;
Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
[TBL] [Abstract][Full Text] [Related]
56. Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban.
Abuan I; Wong KH; Bolinske B; Hale KS
J Pharm Technol; 2019 Jun; 35(3):119-125. PubMed ID: 34860981
[No Abstract] [Full Text] [Related]
57. Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding.
Korobey MJ; Sadaka F; Javed M; Moynihan M; Alsaei A
Neurocrit Care; 2021 Feb; 34(1):112-120. PubMed ID: 32430804
[TBL] [Abstract][Full Text] [Related]
58. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
[TBL] [Abstract][Full Text] [Related]
59. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Ruff CT; Giugliano RP; Antman EM
Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
[TBL] [Abstract][Full Text] [Related]
60. Andexanet Alfa: First Global Approval.
Heo YA
Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
